Autolus Therapeutics (AUTL) Equity Average (2017 - 2025)
Historic Equity Average for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to $306.0 million.
- Autolus Therapeutics' Equity Average fell 3910.13% to $306.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.0 million, marking a year-over-year decrease of 3910.13%. This contributed to the annual value of $269.4 million for FY2024, which is 3136.7% up from last year.
- As of Q3 2025, Autolus Therapeutics' Equity Average stood at $306.0 million, which was down 3910.13% from $358.8 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year Equity Average high stood at $554.9 million for Q2 2024, and its period low was $146.0 million during Q4 2023.
- Its 4-year average for Equity Average is $317.0 million, with a median of $292.2 million in 2022.
- As far as peak fluctuations go, Autolus Therapeutics' Equity Average soared by 20969.68% in 2024, and later crashed by 3910.13% in 2025.
- Quarter analysis of 4 years shows Autolus Therapeutics' Equity Average stood at $229.9 million in 2022, then tumbled by 36.5% to $146.0 million in 2023, then surged by 209.7% to $452.1 million in 2024, then crashed by 32.33% to $306.0 million in 2025.
- Its Equity Average was $306.0 million in Q3 2025, compared to $358.8 million in Q2 2025 and $399.2 million in Q1 2025.